Study design & results
Available in the Gosset platform where reported.
Trial intelligence / Profile preview
Irinotecan and Vincristine in Relapsed Rhabdomyosarcoma
NCT00025363Phase 2Completed
- Sponsor
- National Cancer Institute
- Start
- Nov 2001
- Primary completion
- Oct 2007
- Modality
- Nanoparticles, Monoclonal Antibodies, Small Molecules
- Countries
- 1
01
Overview
Phase 2, randomised, open-label trial of irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumab and tirapazamine in rhabdomyosarcoma (RMS) and undifferentiated sarcoma (2 arms), sponsored by National Cancer Institute. Primary endpoints: Response rate at week 6 of investigational window therapy and Incidence of Dose Limiting Toxicity (DLT) at 6 years. Started Nov 2001; status: completed.
02
Drugs
irinotecan hydrochloride liposome injection (II) + temozolomide + bevacizumabtirapazamine
03
Conditions
rhabdomyosarcoma (RMS)undifferentiated sarcoma
Beyond the preview
Go deeper on NCT00025363.
Study design, results and competitive context are available in the Gosset platform where reported.
Competitive context
Available in the Gosset platform where reported.
Bring the full picture into focus.
See how Gosset can support your research on NCT00025363.